CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 64 enrolled
Drug / intervention
bevacizumab +1 morebiological
Likely dose
Bevacizumab IV (specific dose not stated in eligibility or arms)AI-extracted
Key inclusion· 9
  • ✓Histologically confirmed ovarian epithelial or primary peritoneal carcinoma that is recurrent, persistent, or incurable with standard therapies
  • ✓At least 1 unidimensionally measurable target lesion ≥20 mm by conventional techniques or ≥10 mm by spiral CT, outside prior radiotherapy field
  • ✓Received 1 prior platinum-based chemotherapy regimen; if treatment-free interval <12 months may have second-line platinum therapy with progressive disease
  • ✓No tumors involving major blood vessels
Key exclusion· 9
  • ✕Prior bevacizumab
  • ✕No prior non-cytotoxic chemotherapy for recurrent or persistent disease
  • ✕No pathologic condition with high risk of bleeding
  • ✕No significant traumatic injury within past 28 days

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00022659
NCT00022659Phase 2Completed
CompareCT.gov

A Phase II Evaluation of Bevacizumab (Anti-VEGF Humanized Monoclonal Antibody) (NSC #704865) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma

National Cancer Institute (NCI)·interventional·Posted Jan 27, 2003·Updated Jul 24, 2019

In Brief

A Phase 2 clinical trial evaluating bevacizumab and laboratory biomarker analysis for Primary Peritoneal Cavity Cancer and 2 related conditions. Completed, enrolled 64 participants across 1 site.

Detailed Summary

This phase II trial is to see if bevacizumab works in treating patients who have persistent or recurrent ovarian epithelial cancer or primary peritoneal cancer. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
CountriesUnited States
CollaboratorsGynecologic Oncology Group

Timeline

Phase 2CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 27, 2003
Enrollment StartApr 1, 2002
Primary CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 7.9 yearsPosted 23.4 years ago

Interventions

bevacizumabbiological

Given IV

laboratory biomarker analysisother

Correlative studies